statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Latest Ratings for TSHA
 DateFirmActionFromTo Mar 2022BairdInitiates Coverage OnOutperform Mar 2022Wells FargoInitiates Coverage OnOverweight Dec 2021GuggenheimInitiates Coverage OnBuy
 View...

Evaluating Taysha Gene Therapies: Insights From 7 Financial Analysts

DALLAS, April 05, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for...

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Get Free Report) gapped down before the market opened on Wednesday . The stock had previously closed at $2.71, but opened at $2.65. Taysha Gene Therapies...

Taysha Gene Therapies (NASDAQ:TSHA) Shares Gap Down to $2.71

Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA  Get Free Report) have been assigned an average rating of Buy from the seven analysts that are covering the stock, Marketbeat...

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives $6.57 Consensus PT from Analysts

Truist Financial analyst Joon Lee maintained a Buy rating on Taysha Gene Therapies (TSHA Research Report) today. The company's shares closed yest...

Taysha Gene Therapies (TSHA) Gets a Buy from Truist Financial

Taysha Gene Therapies (NASDAQ:TSHA  Get Free Report)s stock had its buy rating reiterated by research analysts at Canaccord Genuity Group in a report issued on Thursday...

Canaccord Genuity Group Reiterates "Buy" Rating for Taysha Gene Therapies (NASDAQ:TSHA)

Taysha Gene Therapies (NASDAQ:TSHA  Free Report) had its price target hoisted by Chardan Capital from $5.00 to $7.00 in a report issued on Thursday, Benzinga reports. They currently have a buy...

Taysha Gene Therapies (NASDAQ:TSHA) Given New $7.00 Price Target at Chardan Capital

Gagnants
Le titre Etao International Co (NASDAQ:ETAO) a augment mardi de 361,39% 0,66 dollars lors de la session after-market.
L'action Taysha Gene Therapies (NASDAQ:TSHA) a mont de 25,77% 2,83...

12 titres de soins de sant  en mouvement lors de la session apr s-cl ture le 19/03/2024

Taysha Gene Therapies shares are climbing after the company reported its fiscal year 2023 results after the bell Tuesday. The company reported fiscal year 2023 losses of 96 cents per share, compared...

Taysha Gene Therapies Stock Soars On FY23 Results: Here's Why

Figure 1

 REVEAL Phase 1/2 Adolescent and Adult Trial Data from Cohort One

Data from first adult patient in REVEAL Phase 1/2 trial showed TSHA-102 (low dose, 5.7x1014 total vg) was...

Taysha Gene Therapies Reports Full Year 2023 Financial Results and Provides Corporate and Clinical Updates

Taysha Gene Therapies, Inc.is a patient-centric, clinical-stage gene therapy company, which engages in the development and commercialization of adeno-associated viruses (AAV) based gene therapies for the treatment of monogenic diseases of the central nervous system. It also develops multiple gene therapy platforms which include AAV9 Discovery, Novel Capsid, and AAV Redosing. The company was founded by Steven Gray, Berge Minassian, and R. A. Session II in 2019 and is headquartered in Dallas, TX.

Volume	794,093.00
52-Wk High	$3.89
52-Wk Low	$0.50

TSHA Taysha Gene Therapies Inc

About

Feed

News

Sentiment

Earnings

Fundamentals